Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 62.2
(0.97%)
EUR 62.2
(0.97%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 337.96 Million EUR | 8.34% |
| 2022 | 311.94 Million EUR | 27.08% |
| 2021 | 245.47 Million EUR | 8.04% |
| 2020 | 227.19 Million EUR | 43.06% |
| 2019 | 158.81 Million EUR | 67.41% |
| 2018 | 94.86 Million EUR | 25.66% |
| 2017 | 75.49 Million EUR | 12.03% |
| 2016 | 67.38 Million EUR | 5.52% |
| 2015 | 63.85 Million EUR | -5.49% |
| 2014 | 67.56 Million EUR | 15.01% |
| 2013 | 58.74 Million EUR | 4.49% |
| 2012 | 56.22 Million EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 337.97 Million EUR | 0.0% |
| 2024 Q2 | 355.48 Million EUR | 5.18% |
| 2023 FY | 337.96 Million EUR | 8.34% |
| 2023 Q2 | 351.4 Million EUR | 7.44% |
| 2023 Q1 | 327.05 Million EUR | 4.85% |
| 2023 Q3 | 365.67 Million EUR | 4.06% |
| 2023 Q4 | 337.96 Million EUR | -7.58% |
| 2022 Q2 | 265.14 Million EUR | 7.28% |
| 2022 FY | 311.94 Million EUR | 27.08% |
| 2022 Q4 | 311.94 Million EUR | 6.86% |
| 2022 Q3 | 291.93 Million EUR | 10.1% |
| 2022 Q1 | 247.15 Million EUR | 0.68% |
| 2021 Q2 | 198.26 Million EUR | -9.26% |
| 2021 Q1 | 218.49 Million EUR | -3.83% |
| 2021 Q4 | 245.47 Million EUR | 11.19% |
| 2021 Q3 | 220.76 Million EUR | 11.35% |
| 2021 FY | 245.47 Million EUR | 8.04% |
| 2020 Q4 | 227.19 Million EUR | -4.4% |
| 2020 FY | 227.19 Million EUR | 43.06% |
| 2020 Q3 | 237.64 Million EUR | 0.77% |
| 2020 Q2 | 235.83 Million EUR | 23.25% |
| 2020 Q1 | 191.34 Million EUR | 20.49% |
| 2019 Q2 | 121.73 Million EUR | 12.4% |
| 2019 Q4 | 158.81 Million EUR | 7.78% |
| 2019 Q1 | 108.3 Million EUR | 14.18% |
| 2019 FY | 158.81 Million EUR | 67.41% |
| 2019 Q3 | 147.35 Million EUR | 21.04% |
| 2018 Q1 | 81.78 Million EUR | 8.33% |
| 2018 Q3 | 102.55 Million EUR | 12.18% |
| 2018 Q2 | 91.42 Million EUR | 11.78% |
| 2018 FY | 94.86 Million EUR | 25.66% |
| 2018 Q4 | 94.86 Million EUR | -7.5% |
| 2017 Q4 | 75.49 Million EUR | 2.26% |
| 2017 FY | 75.49 Million EUR | 12.03% |
| 2017 Q3 | 73.82 Million EUR | 0.61% |
| 2017 Q2 | 73.37 Million EUR | 1.87% |
| 2017 Q1 | 72.03 Million EUR | 6.89% |
| 2016 FY | 67.38 Million EUR | 5.52% |
| 2016 Q3 | 65.61 Million EUR | 6.09% |
| 2016 Q2 | 61.84 Million EUR | 0.21% |
| 2016 Q1 | 61.71 Million EUR | -3.35% |
| 2016 Q4 | 67.38 Million EUR | 2.71% |
| 2015 Q1 | 69.22 Million EUR | 2.46% |
| 2015 FY | 63.85 Million EUR | -5.49% |
| 2015 Q4 | 63.85 Million EUR | -12.62% |
| 2015 Q3 | 73.07 Million EUR | 4.5% |
| 2015 Q2 | 69.93 Million EUR | 1.02% |
| 2014 Q2 | 66.06 Million EUR | 7.59% |
| 2014 Q1 | 61.4 Million EUR | 4.53% |
| 2014 FY | 67.56 Million EUR | 15.01% |
| 2014 Q4 | 67.56 Million EUR | 6.44% |
| 2014 Q3 | 63.47 Million EUR | -3.92% |
| 2013 Q3 | 60.38 Million EUR | 6.71% |
| 2013 FY | 58.74 Million EUR | 4.49% |
| 2013 Q4 | 58.74 Million EUR | -2.71% |
| 2013 Q1 | 51.48 Million EUR | -8.43% |
| 2013 Q2 | 56.58 Million EUR | 9.91% |
| 2012 Q4 | 56.22 Million EUR | 0.0% |
| 2012 FY | 56.22 Million EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Boiron SA | 96.76 Million EUR | -249.26% |
| Vetoquinol SA | 103.53 Million EUR | -226.419% |
| Valneva SE | 44.46 Million EUR | -660.059% |
| AB Science S.A. | 336 Thousand EUR | -100485.714% |
| Nanobiotix S.A. | 200 Thousand EUR | -168884.0% |
| PHAXIAM Therapeutics S.A. | 671 Thousand EUR | -50267.809% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -33796799900.0% |
| BioSenic S.A. | - EUR | -Infinity% |
| ABIVAX Société Anonyme | 1.00 EUR | -33796799900.0% |
| Formycon AG | 467 Thousand EUR | -72270.021% |